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Overexpression of human DKK1 via rAAV vector-mediated gene transfer 
stimulates chondrogenic differentiation of human bone marrow-derived 
mesenchymal stem cells 
Introduction 
 
In absence of vascularization and of potential delivery 
of chondroreparative progenitor cells, the adult articu-
lar cartilage is not capable of fully recovering from 
injury (trauma, degenerative osteoarthritis), leading to 
a repair tissue of fibrocartilaginous nature (type-I col-
lagen) with poor mechanical properties relative to the 
original hyaline cartilage (type-II collagen, proteogly-
cans) (Frisbie et al. 2003, Madry et al. 2010) even af-
ter surgical interventions like marrow stimulation pro-
cedures (Madry et al. 2010). Repopulation of cartilage 
lesions by administration of mesenchymal stem cells 
(MSCs) such as those originating from the bone mar-
row compartment is a promising approach to enhance 
the repair of damaged articular cartilage (Johnstone et 
al. 2013). Yet, all attempts at implanting MSCs in pa-
tients met limited success, with outcomes associated 
again with the formation of fibrocartilage in sites of 
injury showing poor integration with the surrounding 
unaffected cartilage (Skowroński & Rutka 2013, 
Wakitani et al. 2004). 
 Genetic modification of MSCs prior to re-
implantation in cartilage defects represents a promis-
ing approach to enhance the chondroreparative activi-
ties of this highly specialized tissue (Baksh et al. 2004, 
Cucchiarini & Madry 2010, Evans et al. 2000, Yoo et 
al. 2000). A number of sequences were reported for 
their chondroreparative activities among which genes 
for ECM components (cartilage oligomeric matrix pro-
tein - COMP) (Haleem-Smith et al. 2012), growth fac-
tors and cytokines (transforming growth factor beta - 
TGF-β; bone morphogenetic proteins - BMPs; basic 
fibroblast growth factor - FGF-2; insulin-like growth 
factor I - IGF-I; interleukin 10 - IL-10) (Cucchiarini et 
al. 2011, Frisch et al. 2014a, 2014b, Liu et al. 2015, 
Pagnotto et al. 2007, Steinert et al. 2009, 2012), 
transcription factors (SOX family, zinc finger protein 
145 - ZNF145) (Ikeda et al. 2004, Kim & Im 2011, 
Liu et al. 2011, Venkatesan et al. 2012), signaling 
molecules (Indian hedgehog - Ihh, Wnt11) (Liu et al. 
2014, Steinert et al. 2012), and other therapeutic 
compounds (small interfering RNA - siRNA - against 
the osteogenic Cbfa-1 transcription factor) (Jeon et al. 
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Enhancing the chondroregenerative activities of mes-
enchymal stem cells via therapeutic gene transfer as 
reinforced sources of implantable cells in sites of carti-
lage injury is a promising tool to improve the natural 
processes of cartilage repair. In the present study, we 
show that overexpression of the Dickkopf-related pro-
tein 1 (DKK1) via clinically adapted recombinant 
adeno-associated viral (rAAV) vectors is capable of 
significantly stimulating proliferative, anabolic, and 
chondrodifferentiation events in primary human mes-
enchymal stem cells compared with control (reporter 
rAAV lacZ) transduction over an extended period of 
time in vitro (21 days). Strikingly, administration of 
the rAAV DKK1 candidate vector concomitantly re-
strained unwanted osteogenic and hypertrophic differ-
entiation outcomes in these cells. These findings reveal 
the possible future benefits of such an approach to treat 
articular cartilage lesions in relevant experimental 
models in vivo. 
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2012). However, thus far none of these candidates 
proved reliably effective to treat sites of cartilage 
injury in vivo (Cucchiarini & Madry 2005), showing 
the critical need to identify new targets for therapy. 
 The goal of the present study was to evidence 
potential metabolic and chondrogenic effects of the 
Dickkopf-related protein 1 (DKK1), an inhibitor of the 
canonical wingless-type (Wnt) signaling pathway in-
volved in patterning, joint development, and progeni-
tor cell differentiation in osteoblasts (Fedi et al. 1999, 
Glinka et al. 1998, Sandell & Adler 1999), in light of 
the protective effects of this factor against cartilage 
destruction and osteophyte formation in experimental 
models of osteoarthritis (Funck-Brentano et al. 2014, 
Oh et al. 2012). To achieve this goal, a sequence cod-
ing for DKK1 was delivered to human MSCs (hMSCs) 
via recombinant adeno-associated viral (rAAV) vec-
tors as these constructs are known to transduce such 
cells at elevated efficiencies (up to 100%) for pro-
longed periods of time (at least 3 weeks in vitro) and 
without impeding their potential for differentiation 
(Cucchiarini et al. 2011, Pagnotto et al. 2007, 
Venkatesan et al. 2012), making rAAV the currently 
best suited systems for translational orthopaedic appli-
cations (Evans & Huard 2015, Madry & Cucchiarini 
2016). 
 The present work demonstrates that effective, 
prolonged overexpression of DKK1 can be achieved in 
hMSCs via rAAV-mediated gene transfer, leading to 
enhanced levels of cell proliferation, ECM deposition, 
and chondrogenic differentiaton in the cells relative to 
control treatments and to the prevention of undesirable 
osteogenic/hypertrophic differentiation in vitro. These 
findings provide a basis to further test the current 
rAAV DKK1 construct as a promising tool to treat 
articular cartilage defects in vivo. 
 
Materials and Methods 
 
Reagents 
All reagents were from Sigma (Munich, Germany) 
unless otherwise indicated. Recombinant FGF-2 was 
purchased at Peprotech (Hamburg, Germany). Recom-
binant TGF-β3 was from R&D Systems (Wiesbaden, 
Germany). Dimethylmethylene blue was from Serva 
(Heidelberg, Germany). The anti-DKK1 antibody (B-
7) was from Santa Cruz Biotechnology, Inc. 
(Heidelberg, Germany), the anti-type-II collagen (II-
II6B3) antibody from the NIH Hybridoma Bank 
(University of Iowa, Ames, USA), the anti-type-I col-
lagen (COL-1) antibody from Abcam (Cambridge, 
UK), and the anti-type-X collagen (COL-10) antibody 
from Sigma. Secondary biotinylated secondary anti-
bodies and the ABC kit were from Vector Laboratories 
(Grünberg, Germany). The DKK1 enzyme-linked im-
mu-nosorbent assay (Quantikine Human Dkk-1 
ELISA) was from R&D Systems and the type-II colla-
gen ELISA (Arthrogen-CIA Capture ELISA kit) from 
Chondrex (Redmond, WA, USA). 
 
Cell culture 
Bone marrow aspirates (~ 10 ml) were obtained from 
the distal femurs of donors undergoing total knee ar-
throplasty (n = 8) (age 75 ± 3 years). The study was 
approved by the Ethics Committee of the Saarland 
Physicians Council (Ha06/08). All patients provided 
informed consent to participate in the study before in-
clusion in the study. All procedures were in accor-
dance with the Helsinki Declaration. All patients pro-
vided informed consent to report individual patient 
data. hMSCs were isolated and expanded in culture 
according to standard protocols (Venkatesan et al. 
2012). Briefly, aspirates were washed in Dulbecco’s 
modified Eagle’s medium (DMEM) and centrifuged, 
and the pellet was resuspended in Red Blood Cell 
Lysing Buffer in DMEM (1:1). The resulting fraction 
was washed, pelleted, and resuspended in DMEM con-
taining 10% fetal bovine serum with 100 U/ml penicil-
lin and 100 μl/ml streptomycin (growth medium). 
Cells were plated in T75 flasks and maintained at 37°C 
in a humidified atmosphere with 5% CO2. The medium 
was exchanged after 24 h and every 2-3 days thereafter 
using growth medium with recombinant FGF-2 (1 ng/
ml). Cells were detached and replated for further ex-
periments at the appropriate densities. hMSCs were 
analyzed by flow cytometry for expression of stem cell 
surface markers (CD71+, CD105+, CD34-) (Venkatesan 
et al. 2012). All experiments were performed with 
cells at no more than passage 2. 
 
Plasmids and rAAV vectors 
The constructs were derived from pSSV9, an AAV-2 
genomic clone (Samulski et al. 1987, 1989). rAAV-
lacZ carries the lacZ gene for E. coli β-galactosidase (β
-gal) (Cucchiarini et al. 2003, Venkatesan et al. 2012). 
A human DKK1 sequence (0.8 kb) (Origene) was 
cloned in place of the lacZ gene in rAAV-lacZ 
(Cucchiarini et al. 2003). The resulting plasmid vector 
is rAAV-hDKK1 where the presence of the DKK1 
fragment was confirmed by sequencing. In both vec-
tors, transgene expression is placed under the control 
of the cytomegalovirus immediate-early (CMV-IE) 
promoter (Cucchiarini et al. 2003, Venkatesan et al. 
2012). The vectors were packaged as conventional (not 
self-complementary) vectors using a helper-free, two-
plasmid transfection system in the 293 packaging cell 
line (an adenovirus-transformed human embryonic 
kidney cell line) with the packaging plasmid pXX2 
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and the Adenovirus helper plasmid pXX6 as previ-
ously described (Venkatesan et al. 2012). The vector 
preparations were purified by dialysis and titered by 
real-time PCR (Cucchiarini et al. 2003, Venkatesan et 
al. 2012), averaging 1010 transgene copies/ml (viral 
particles to functional vectors = 500/1). 
 
rAAV-mediated gene transfer 
Cells were transduced with rAAV vectors in 
monolayer culture (2 x 104 cells, 20 μl vector, i.e. 4 x 
105 functional recombinant viral particles and MOI = 
20) and kept in growth medium for up to 21 days 
(Venkatesan et al. 2012). hMSC aggregate cultures (2 
× 105 cells) were prepared and kept in defined chon-
drogenic medium (high-glucose DMEM 4.5 g/l, peni-
cillin/streptomycin, 6.25 μg/ml insulin, 6.25 μg/ml 
transferrin, 6.25 μg/ml selenous acid, 5.35 μg/ml li-
noleic acid, 1.25 μg/ml bovine serum albumin, 1 mM 
sodium pyruvate, 37.5 mg/ml ascorbate 2-phosphate, 
10-7 M dexamethasone, 10 ng/ml TGF-β3) for trans-
duction with rAAV (40 μl vector, i.e. 8 x 105 func-
tional recombinant viral particles, i.e. MOI = 4) for up 
to 21 days (Venkatesan et al. 2012). 
 
Transgene expression 
Transgene (DKK1) expression was assayed by ELISA 
(Cucchiarini et al. 2011, Venkatesan et al. 2012). 
Briefly, samples (monolayer and aggregate cultures) 
were washed twice and maintained for 24 h in serum-
free medium prior to collection of the supernatants of 
culture at the denoted time points for centrifugation to 
separate debris. Measurements were carried out on a 
GENios spectrophotometer/fluorometer (Tecan, Crail-
sheim, Germany). DKK1 expression was also moni-
tored by immunocyto-/histochemistry on fixed 
monolayer cultures and on paraffin-embedded sections 
of aggregates (5 μm), respectively, using a specific 
primary antibody (1:100), a biotinylated secondary 
antibody, and the ABC method with diaminobenzidine 
(DAB) as the chromogen (Venkatesan et al. 2012). 
Samples were examined by light microscopy (BX 45; 
Olympus, Hamburg, Germany) (Venkatesan et al. 
2012). To control for secondary immunoglobulins, 
samples were processed with omission of the primary 
antibody. 
 
Biochemical assays 
Cultures were harvested and digested with papain 
(Venkatesan et al. 2012). The DNA and proteoglycan 
contents were determined with a fluorimetric assay 
using Hoechst 22358 and by binding to dimethyl-
methylene blue dye, respectively (Venkatesan et al. 
2012). The type-II collagen contents were monitored 
by ELISA (Venkatesan et al. 2012). Data were nor-
malized to total cellular proteins using a protein assay 
(Pierce Thermo Scientific, Fisher Scientific, Schwerte, 
Germany). All measurements were performed with a 
GENios spectrophotometer/fluorometer. 
 
Histological, immunocytochemical, and immunohis-
tochemical analyses 
Cultures were harvested and fixed in 4% formalin, de-
hydrated in graded alcohols, embedded in paraffin, and 
sectioned (3 μm). Sections were stained with toluidine 
blue (matrix proteoglycans) and alizarin red (matrix 
mineralization) (Venkatesan et al. 2012). Expression 
of type-II and -X collagen was detected by immuno-
histochemistry using specific primary antibodies, bioti-
nylated secondary antibodies, and the ABC method 
with DAB (Venkatesan et al. 2012). To control for 
secondary immunoglobulins, sections were processed 
with omission of the primary antibody. Samples were 
examined under light microscopy (BX 45; Olympus). 
 
Histomorphometry 
The evaluations were performed at four random stan-
dardized sites in monolayer cultures or using ten serial 
histological and immunohistochemical sections of ag-
gregate cultures for each parameter, test, and replicate 
condition with the SIS analySIS program (Olympus), 
Adobe Photoshop (Adobe Systems, Unterschleissheim, 
Germany), and Scion Image (Scion Corporation, Fre-
derick, MD, USA) (Venkatesan et al. 2012). The trans-
duction efficiencies were calculated as the % of X-Gal-
stained cells to the total numbers of cells (Venkatesan 
et al. 2017). Toluidine blue and alizarin red staining 
and type-II and -I collagen immunostaining were 
scored for uniformity and intensity according to a 
modified Bern Score grading system (Venkatesan et 
al. 2017) as: 0 (no staining), 1 (heterogeneous and/or 
weak staining), 2 (homogeneous and/or moderate 
staining), 3 (homogeneous and/or intense staining), 
and 4 (very intense staining). Type-X collagen expres-
sion was monitored by estimating the percentage of 
positively stained cells to the total numbers of cells on 
immunohistochemical sections. All sections were 
scored blind by two individuals with regard to the con-
ditions. 
 
Real-time PCR analysis 
Total cellular RNA was extracted from the cultures 
using the RNeasy Protect Mini Kit with an on-column 
RNase-free DNase treatment (Qiagen, Hilden, Ger-
many). RNA was eluted in 30 μl RNase-free water. 
Reverse transcription was carried out with 8 μl eluate 
using the 1st Strand cDNA Synthesis kit for RT-PCR 
(AMV; Roche Applied Science) (Venkatesan et al. 
2012). An aliquot of the cDNA product (2 μl) was am-
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plified with real-time PCR using the Brilliant SYBR 
Green QPCR Master Mix (Stratagene, Agilent Tech-
nologies, Waldbronn, Germany) on an Mx3000P 
QPCR operator system (Stratagene) as follows: initial 
incubation (95°C, 10 min), amplification for 55 cycles 
(denaturation at 95°C, 30 sec; annealing at 55°C, 1 
min; extension at 72°C, 30 sec), denaturation (95°C, 1 
min), and final incubation (55°C, 30 sec) (Venkatesan 
et al. 2012). The primers (Invitrogen, Darmstadt, Ger-
many) used were SOX9 (chondrogenic marker) 
(forward, 5′-ACACACAGCTCACTCGACCTTG-3′; 
reverse, 5′-GGGAATTCTGGTTGGTCCTCT-3′), type
-II collagen (COL2A1; chondrogenic marker) 
(forward, 5′-GGACTTTTCTCCCCTCTCT-3′; reverse, 
5′-GACCCGAAGGTCTTACAGGA-3′), type-I colla-
gen (COL1A1; osteogenic marker) (forward 5’-
ACGTCCTGGTGAAG TTGGTC-3’; reverse 5’-
ACCAGGGAAGCCTCTCTCTC- 3’), type-X colla-
gen (COL10A1; marker of hypertrophy) (forward 5’-
CCCTCTTGTTAG TGCCAACC-3’; reverse 5’-
AGATTCCAGTCCTTGGGTCA-3’), runt-related 
transcription factor 2 (RUNX2; osteogenic marker) 
(forward 5’-GCAGTTCCCAAGCATTTCAT-3’; re-
verse 5’-CACTCTGGCTTTGGAAAGAG-3’), b-
catenin (mediator of the Wnt signaling pathway for 
osteoblast lineage differentiation) (forward 5’-
CAAGTGGGTGGTATAGAGG-3’; reverse 5’-
GCGGGACAAAGGGCAAGA-3’), and glyceralde-
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Figure 1. Detection of transgene (DKK1) expression in rAAV-transduced hMSCs. Cells in monolayer cultures (n = 24 using 8 
bone marrow aspirates in three independent experiments) (A) and aggregate cultures (n = 24 using 8 bone marrow aspirates in 
three independent experiments) (B) were transduced in triplicate with rAAV-hDKK1 (n = 72 for each type of culture) or rAAV
-lacZ (n = 72 for each type of culture) (A: 20 μl each vector, MOI = 20; B: 40 μl each vector, MOI = 4) and all the cultures and 
conditions were processed after 21 days to detect DKK1 expression by specific immunocyto-/histochemistry as described in 
the Materials and Methods (magnification x20; all representative data). 
  
hyde-3-phosphate dehydrogenase (housekeeping gene 
a n d  i n t e r n a l  c o n t r o l )  ( f o r w a r d ,  5 ′ -
GAAGGTGAAGGTCGGAGTC-3′; reverse, 5′-
GAAGATGGTGATGGGATTTC-3′) (all 150 nM fi-
nal concentration) (Venkatesan et al. 2012). Control 
conditions included reactions using water and nonre-
verse-transcribed mRNA. Specificity of the products 
was confirmed by melting curve analysis and agarose 
gel electrophoresis. The threshold cycle (Ct) value for 
each gene of interest was measured for each amplified 
sample using MxPro QPCR software (Stratagene), and 
values were normalized to glyceraldehyde-3-phosphate 
dehydrogenase expression by using the 2-ΔΔCt method, 
as described previously (Venkatesan et al. 2012). 
 
Statistical analysis 
All bone marrow aspirates (n = 8) were used and tested 
independently for all the tests performed here (ELISA; 
biochemical, histological, immunocytochemical, and 
immunohistochemical analyses; histomorphometry; 
real-time reverse transcription polymerase chain reac-
tion analyses) and for each replicate condition. Each 
condition (undifferentiated monolayer cell cultures and 
chondrogenically-induced aggregate cultures; cells 
transduced with rAAV-hDKK1 versus rAAV-lacZ 
with respective MOIs; variable time points) was per-
formed in triplicate in three independent experiments. 
Three monolayer cultures were analyzed at four 
random standardized sites for each test and replicate 
condition.  Ten serial  his tological  and 
immunohistochemical sections of aggregate cultures 
were analyzed for each test and replicate condition. 
Data are expressed as mean ± standard deviation (SD) 
of separate experiments. Statistical analysis was 
performed using SPSS version 23 (IBM, Armonk, NY, 
USA) and the t-test was employed to compare related 
samples to evaluate differences between groups. P val-
ues of less than 0.05 were considered statistically sig-
nificant. 
 
Results 
 
DKK1 overexpression in human bone marrow-
derived mesenchymal stem cells 
Human bone marrow-derived mesenchymal stem cells 
(hMSCs) were first transduced with rAAV-hDKK1 in 
undifferentiated monolayer cultures to evaluate the 
feasibility of overexpressing this factor in these cells 
relative to the control rAAV-lacZ condition. Highly 
effective, sustained DKK1 expression was signifi-
cantly achieved in rAAV-hDKK1-transduced hMSCs 
over a prolonged period of time (21 days), reaching 97 
± 3% transduction efficiencies versus 12 ± 3% in the 
presence of rAAV-lacZ (8.1-fold difference, P ≤ 
0.001) (Figure 1A). An estimation of the DKK1 pro-
duction levels by ELISA in the samples revealed sig-
nificantly higher amounts of factor synthesis with 
rAAV-hDKK1 relative to rAAV-lacZ at any time point 
of the analysis (up to 36-fold difference, P ≤ 0.001) 
(Table 1). 
 hMSCs were next transduced with rAAV-
hDKK1 in chondrogenically-induced aggregate cul-
tures to further evidence the levels of DKK1 expres-
sion in such a specific environment compared with 
control rAAV-lacZ treatment. Concordant with the 
findings in monolayer culture, a strong, significant 
signal was again noted in the DKK1-treated aggregates 
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System 
rAAV-lacZ rAAV-hDKK1 
Day 3 Day 7 Day 21 Day 3 Day 7 Day 21 
 Monolayer 
cultures 
0.05 
(0.01) 
0.02 
(0.01) 
0.01 
(0.01) 
0.60 
(0.03)* 
0.42 
(0.04)* 
0.36 
(0.03)* 
 Aggregate 
cultures 
0.01 
(0.01) 
0.01 
(0.01) 
0.01 
(0.01) 
0.18 
(0.02)* 
0.14 
(0.02)* 
0.11 
(0.01)* 
Table 1. DKK1 expression in rAAV-transduced undifferentiated hMSC monolayer cultures and in chondrogenically-induced 
hMSC aggregate cultures. 
 Assay  rAAV-lacZ rAAV-hDKK1 
 DNA (ng/mg total proteins)  0.16 (0.02) 0.19 (0.03)* 
 Proteoglycans (μg/mg total proteins)  2.2 (0.4) 3.4 (0.6)* 
 Type-II collagen (ng/mg total proteins)  66.1 (12.2) 101.4 (17.3)* 
 Proteoglycans/DNA (μg/ng)  13.8 (1.2) 17.9 (1.8)* 
 Type-II collagen/DNA (ng/ng) 412.5 (20.3) 531.6 (28.4)* 
Table 2. Biochemical analyses in rAAV-transduced chondrogenically-induced hMSC aggregate cultures (day 21). 
fold difference, P ≤ 0.001) (Table 2). Successful chon-
drogenic differentiation was achieved in the aggregates 
after 21 days, most particularly when applying the 
rAAV-hDKK1 vectors versus control lacZ gene trans-
fer as seen by the more intense toluidine blue staining 
and type-II collagen immunostaining (1.4- and 1.6-fold 
difference, respectively, P ≤ 0.001) (Figure 2 and Ta-
ble 3). Concordant with that, the proteoglycan and type
-II collagen contents were significantly more elevated 
using the DKK1 vector compared with rAAV-lacZ at 
this prolonged time point (always 1.5-fold difference, 
respectively, P ≤ 0.001) (Table 2). Furthermore, an 
evaluation of the proteoglycan and type-II collagen 
contents normalized to the proliferation indices re-
vealed significantly higher amounts of this major ma-
trix components with rAAV DKK1 relative to lacZ on 
day 21 (always 1.3-fold difference, respectively, P ≤ 
0.001) (Table 2). In marked contrast, the deposition of 
undesirable type-I and type-X collagen osteogenic and 
hypertrophic markers was almost completely pre-
65   Journal of Molecular Biochemistry, 2018    
(98 ± 2% transduction efficiencies) versus lacZ trans-
duction (18 ± 2%, i.e. a 5.4-fold difference, P ≤ 0.001) 
over a selected time (21 days) adapted to achieve 
hMSC chondrogenesis (Venkatesan et al. 2012) 
(Figure 1B). Also, the levels of DKK1 produced in the 
rAAV-hDKK1-transduced aggregates were always 
significantly higher than those measured in the rAAV-
lacZ-transduced samples (up to 18-fold difference, P ≤ 
0.001) (Table 1). 
 
Effects of DKK1 overexpression 
Chondrogenically-induced aggregate cultures of 
hMSCs were then treated with rAAV-hDKK1 to moni-
tor the potential effects of DKK1 overexpression on 
the metabolic activities and chondrogenic differentia-
tion processes in the cells over time in this environ-
ment compared with control (rAAV-lacZ) treatment. 
 Application of the DKK1 vector significanlty 
increased the DNA contents in the hMSC aggegrate 
cultures after 21 days relative to lacZ treatment (1.2-
Figure 2. Metabolic and chondrogenic differentiation processes in rAAV-transduced chondrogenically-induced hMSCs. 
Aggregate cultures (n = 24 using 8 bone marrow aspirates in three independent experiments) were transduced in triplicate with 
rAAV-hDKK1 (n = 72) or rAAV-lacZ (n = 72) (40 μl vector, MOI = 4) as described in Figure 1 and processed after 21 days 
for toluidine blue staining (n = 10 histological sections analyzed per replicate condition for each vector, i.e. n = 30 for rAAV-
hDKK1 and n = 30 for rAAV-lacZ to represent all aggregate cultures) and immunodetection of type-II collagen (n = 10 immu-
nohistochemical sections analyzed per replicate condition for each vector, i.e. n = 30 for rAAV-hDKK1 and n = 30 for rAAV-
lacZ to represent all aggregate cultures) (magnification x10; all representative data) as described in the Materials and Methods. 
vented by addition of rAAV-hDKK1 over this period 
of evaluation compared with the elevated levels of ex-
pression of these components in the presence of rAAV
-lacZ (9.3- and 48-fold difference, respectively, P ≤ 
0.001), together with a significant reduction of alizarin 
red staining (1.5-fold, P ≤ 0.001) (Figure 3 and Table 
3). 
 
Gene expression profiles in human bone marrow-
derived mesenchymal stem cells following DKK1 
overexpression 
hMSCs in chondrogenically-induced aggregate cul-
tures were finally modified with rAAV-hDKK1 to ex-
amine the influence of DKK1 overexpression on the 
gene expression profiles in the cells over time relative 
to control (rAAV-lacZ) treatment. As we previously 
reported that rAAV gene transfer does not impair 
hMSC chondrogenesis (Venkatesan et al. 2012), we 
did not further include here a condition without vector 
treatment as additional control. 
 Overall, the results of the real-time RT-PCR 
analysis corroborated the findings of the histological, 
immunohistochemical, and biochemical analyses. Ad-
ministration of the rAAV DKK1 vector significantly 
increased the levels of SOX9 and COL2A1 expression 
over the period of evaluation (21 days) relative to the 
control lacZ condition (2.7- and 1.9-fold difference, 
respectively, P ≤ 0.001) while decreasing that of 
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Parameter rAAV-lacZ rAAV-hDKK1 
Toluidine blue staining 2.7 (0.5) 3.7 (0.6)* 
Type-II collagen immunostaining 2.4 (0.5) 3.9 (0.4)* 
Alizarin red staining 3.4 (0.5) 2.3 (0.6)* 
Type-I collagen immunostaining 3.7 (0.5) 0.4 (0.1)* 
Type-X collagen immunostaining 95 (7) 2 (1)* 
Table 3. Histomorphometric analyses in rAAV-transduced chondrogenically-induced hMSC aggregate cultures (day 21). 
Figure 3. Hypertrophic and 
osteogenic differentiation processes 
in rAAV-transduced chondrogeni-
cally-induced hMSCs. Aggregate 
cultures (n = 24 using 8 bone mar-
row aspirates in three independent 
experiments) were transduced in 
triplicate with rAAV-hDKK1 (n = 
72) or rAAV-lacZ (n = 72) (40 μl 
vector, MOI = 4) as described in 
Figures 1 and 2 and processed after 
21 days for alizarin red staining (n = 
10 histological sections analyzed per 
replicate condition for each vector, 
i.e. n = 30 for rAAV-hDKK1 and n 
= 30 for rAAV-lacZ to represent all 
aggregate cultures) and immu-
nodetection of type-I collagen (n = 
10 immunohistochemical sections 
analyzed per replicate condition for 
each vector, i.e. n = 30 for rAAV-
hDKK1 and n = 30 for rAAV-lacZ 
to represent all aggregate cultures) 
and of type-X collagen (n = 10 im-
munohis tochemica l  sec t io ns 
analyzed per replicate condition for 
each vector, i.e. n = 30 for rAAV-
hDKK1 and n = 30 for rAAV-lacZ 
to represent all aggregate cultures) 
(magnification x10; all representa-
tive data) as described in the Materi-
als and Methods. 
COL1A1 and COL10A1 (3.8- and 7.7-fold difference, 
respectively, P ≤ 0.001), in association with reduced 
RUNX2 and β-catenin expression (2.4- and 2.2-fold 
difference, respectively, P ≤ 0.001) (Figure 4). 
 
Discussion 
 
Application of genetically modified chondroreparative 
MSCs may provide powerful tools to address the prob-
lem of the inappropriate formation of fibrocartilagi-
nous tissue in sites of cartilage injury occurring during 
spontaneous repair and following classical or MSC-
guided surgical interventions (Madry et al. 2010, 
Skowroński & Rutka 2013, Wakitani et al. 2004). 
While a number of candidate factors have been re-
ported for their chondroregenerative potential in these 
cells (COMP, TGF-β, BMPs, FGF-2, IGF-I, IL-10, 
SOX and ZNF145 transcription factors, signaling Ihh 
and Wnt11 molecules, anti-Cbfa-1 siRNA) 
(Cucchiarini et al. 2011, Frisch et al. 2014a, 2014b, 
Haleem-Smith et al. 2012, Ikeda et al. 2004, Jeon et al. 
2012, Kim & Im 2011, Liu et al. 2011, 2014, 2015, 
Pagnotto et al. 2007, Steinert et al. 2009, 2012, 
Venkatesan et al. 2012), there is no evidence to date 
demonstrating the consistent and full regeneration of a 
hyaline cartilage using any of these agents in vivo 
(Cucchiarini & Madry 2005). The goal of the present 
study therefore was to identify novel factors capable of 
enhancing MSC chondrogenesis in vitro as a first step 
towards future evaluations in relevant animal models 
of cartilage defects in vivo (Cucchiarini & Madry 
2005, Liu et al. 2011, Pagnotto et al. 2007). We 
focused on delivering a genetic sequence coding for 
the chondroprotective DKK1 inhibitor of the Wnt 
signaling pathway (Funck-Brentano et al. 2014, Oh et 
al. 2012) via the highly potent rAAV vectors that are 
well adapted for clinical applications (Evans & Huard 
2015, Madry & Cucchiarini 2016). 
 Our results first reveal that highly effective 
and prolonged expression of DKK1 may be obtained 
via rAAV gene transfer in both undifferentiated and 
chondrogenically-induced hMSCs versus control 
(lacZ) treatment over a period of 21 days (the longest 
time point examined), reaching 98% transduction effi-
ciencies, concordant with previous findings using this 
class of vector (Cucchiarini et al. 2011, Pagnotto et al. 
2007, Venkatesan et al. 2012). The levels of DKK1 
factor produced ranged from 0.60 ± 0.03 to 0.36 ± 0.03 
pg/ml/106 cells/24 h between days 3 and 21 in undif-
ferentiated hMSC monolayer cultures and from 0.18 ± 
0.02 to 0.11 ± 0.01 pg/ml/106 cells/24 h in chondro-
genically-induced hMSC aggregate cultures (i.e. an 
about 3.3-fold difference between systems when com-
paring similar time points, probably reflecting the 5-
fold difference of MOIs: MOI = 20 in monolayer cul-
tures versus MOI = 4 in aggregate cultures). In all 
cases, significant and durable levels of expression were 
noted relative to control treatment, most likely due to 
the good maintenance of the rAAV transgene in the 
targets (Xiao et al. 1996). 
 The data next indicate that successful DKK1 
overexpression in hMSCs using rAAV led to enhanced 
cell proliferation levels over an extended period of 
time (21 days) relative to lacZ treatment, owing to the 
durable production of DKK1 from the construct. This 
is in good agreement with previous observations show-
ing increased proliferation promoted by recombinant 
DKK1 (rDKK1) in such cells (Gregory et al. 2003) but 
in contrast with findings from the Im’s group (Im et al. 
2010, 2011) who reported decreased proliferation indi-
ces when applying rDKK1 to hMSCs. However, in 
these studies such effects were described after 6 days 
of treatment using high doses of factor (300 ng/ml) 
while Gregory et al. (Gregory et al. 2003) applied 
DKK1 at 100 ng/ml (i.e. 3-fold less) and we reported 
maximal DKK1 production levels of 0.60 pg/ml/106 
cells 24 h with rAAV, overall suggesting that 
balancing DDK1 expression will be critical for optimal 
therapeutic benefits. 
 The current results also show that administra-
tion of rAAV-hDKK1 was capable of stimulating over 
time the anabolic and differentiation activities of 
hMSCs (proteoglycans, type-II collagen) versus rAAV
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Figure 4. Gene expression analysis in rAAV-transduced 
chondrogenically-induced hMSCs. Aggregate cultures (n = 
24 using 8 bone marrow aspirates in three independent 
experiments) were transduced in triplicate with rAAV-
hDKK1 (n = 72) or rAAV-lacZ (n = 72) (40 μl vector, MOI 
= 4) as described in Figures 1-3 and all the cultures and 
conditions were processed after 21 days to monitor the gene 
expression profiles of the transcription factor SOX9, type-II 
collagen (COL2A1), type-I collagen (COL1A1), and type-X 
collagen (COL10A1), the transcription factor RUNX2, and β
-catenin, with GAPDH serving as a housekeeping gene and 
internal control. Ct values were obtained for each target gene 
using GAPDH as a control for normalization and fold 
inductions (relative to lacZ aggregates) were measured by 
using the 2-ΔΔCt method as described in the Materials and 
Methods. *Statistically significant compared with rAAV-
lacZ.  
-lacZ, also probably resulting from the steady overex-
pression of DKK1 via rAAV that led to enhanced lev-
els of chondrogenic SOX9 expression as reported by 
others (Im & Quan 2010). Such chondroreparative ef-
fects of DKK1 are overall consistent with previous 
observations using rDKK1 to target MSCs (Im & 
Quan 2010; Leijten et al. 2012) or by indirectly block-
ing this factor with an anti-DKK1 antibody (Zhong et 
al. 2016). 
 Finally, the data demonstrate that modification 
of hMSCs by rAAV DKK1 gene transfer advanta-
geously reduced unwanted hypertophic and ostegenic 
events in the cells (mineralization, type-I and -X colla-
gen), via decreased levels of RUNX2 (osteogenic tran-
scription factor) and β-catenin (mediator of the Wnt 
signaling pathway for osteoblast lineage 
differentiation) versus increased expression profiles of 
SOX9 (a well-known factor with anti-hypertrophic 
activities) (Akiyama et al. 2004, Amano et al. 2009, 
Hattori et al. 2010, Leung et al. 2011, Venkatesan et 
al. 2012), all in good agreement with the properties of 
DKK1 (Fedi et al. 1999, Glinka et al. 1998, Sandell & 
Adler 1999) and with previous findings using rDKK1 
(Gregory et al. 2003, Im & Quan 2010, Leijten et al. 
2012) or by indirect anti-DKK1 neutralization (Zhong 
et al. 2016). 
 In conclusion, the present findings show the 
benefits of modifying hMSCs via rAAV to overex-
press DKK1 for chondroregenerative purposes. The 
next step will be to translate the findings in animal 
cells as a preliminary approach to evaluations in clini-
cally relevant (orthotopic) experimental models of car-
tilage defects in vivo (Cucchiarini & Madry 2005, Liu 
et al. 2011, Pagnotto et al. 2007) to evidence potential 
therapeutic and confirm the anti-hypertrophic activities 
of DKK1. This will be also critical to exclude any de-
cisive impact on bone homeostasis and osteoarthritis 
(Krause et al. 2014, Mason et al. 2017, Weng et al. 
2010). In this regard, a close modulation of DKK1 ex-
pression may be envisaged by tight gene regulation 
using tissue-specific (SOX9, type-II collagen, COMP) 
or regulatable promoters (tetracycline-sensitive) 
(Apparailly et al. 2002, Goldring et al. 1994). Overall, 
the current findings are valuable to further develop 
effective approaches for the treatment of articular car-
tilage lesions. 
 
Conflicts of interest 
 
The authors declare no conflict of interest associated 
with this work. 
 
 
 
Author Contributions 
 
MC designed the study and drafted the manuscript. 
JKV carried out the major experiments and contributed 
in manuscript writing. GS, SS-M, and HM helped in 
histological, immunohistochemical, and histomor-
phometric experiments. All authors read and approved 
the final version of the manuscript. 
 
Funding information 
 
This work was funded by the German Osteoarthritis 
Foundation (Deutsche Arthrose-Hilfe e.V.). The au-
thors thank R. J. Samulski (The Gene Therapy Center, 
University of North Carolina, Chapel Hill, NC), X. 
Xiao (The Gene Therapy Center, University of Pitts-
burgh, Pittsburgh, PA), and E. F. Terwilliger (Division 
of Experimental Medicine, Harvard Institutes of Medi-
cine and Beth Israel Deaconess Medical Center, Bos-
ton, MA) for providing genomic adeno-associated vec-
tor 2 plasmid clones and the 293 cell line. 
 
References 
 
Akiyama H, Lyons JP, Mori-Akiyama Y, Yang X, 
Zhang R, Zhang Z, Deng JM, Taketo MM, Nakamura 
T, Behringer RR, McCrea PD & de Crombrugghe B 
2004 Interactions between Sox9 and beta-catenin con-
trol chondrocyte differentiation. Genes Dev 18 1072-
1087 
Amano K, Hata K, Sugita A, Takigawa Y, Ono K, Wa-
kabayashi M, Kogo M, Nishimura R & Yoneda T 2009 
Sox9 family members negatively regulate maturation 
and calcification of chondrocytes through up-
regulation of parathyroid hormone-related protein. Mol 
Biol Cell 20 4541-4551 
Apparailly F, Millet V, Noël D, Jacquet C, Sany J & 
Jorgensen C 2002 Tetracycline-inducible interleukin-
10 gene transfer mediated by an adeno-associated vi-
rus: application to experimental arthritis. Hum Gene 
Ther 13 1179-1188 
Baksh D, Song L & Tuan RS 2004 Adult mesenchy-
mal stem cells: characterization, differentiation, and 
application in cell and gene therapy. J Cell Mol Med 8 
301-316 
Cucchiarini M, Ren XL, Perides G & Terwilliger EF 
2003 Selective gene expression in brain microglia me-
diated via adeno-associated virus type 2 and type 5 
vectors. Gene Ther 10 657-667 
Cucchiarini M & Madry H 2005 Gene therapy for car-
tilage defects. J Gene Med 7 1495-1509 
Cucchiarini M & Madry H 2010 Genetic modification 
of mesenchymal stem cells for cartilage repair. Biomed 
Mater Eng 20 135-143 
Journal of Molecular Biochemistry, 2018   68 
Cucchiarini M, Ekici M, Schetting S, Kohn D & Ma-
dry H 2011 Metabolic activities and chondrogenic dif-
ferentiation of human mesenchymal stem cells follow-
ing recombinant adeno-associated virus-mediated gene 
transfer and overexpression of fibroblast growth factor 
2. Tissue Eng Part A 17 1921-1933 
Evans CH, Ghivizzani SC, Smith P, Shuler FD, Mi Z 
& Robbins PD 2000 Using gene therapy to protect and 
restore cartilage. Clin Orthop Relat Res 379 Suppl 
S214-S219 
Evans CH & Huard J 2015 Gene therapy approaches to 
regenerating the musculoskeletal system. Nat Rev 
Rheumatol 11 234-242 
Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, 
Bottaro DP, Kraus MH & Aaronson SA 1999 Isolation 
and biochemical characterization of the human Dkk-1 
homologue, a novel inhibitor of mammalian Wnt sig-
naling. J Biol Chem 274 19465-19472 
Frisbie DD, Oxford JT, Southwood L, Trotter GW, 
Rodkey WG, Steadman JR, Goodnight JL & McIl-
wraith CW 2003 Early events in cartilage repair after 
subchondral bone microfracture. Clin Orthop Relat 
Res 407 215-227 
Frisch J, Venkatesan JK, Rey-Rico A, Schmitt G, Ma-
dry H & Cucchiarini M 2014a Influence of insulin-like 
growth factor I overexpression via recombinant adeno-
associated vector gene transfer upon the biological ac-
tivities and differentiation potential of human bone 
marrow-derived mesenchymal stem cells. Stem Cell 
Res Ther 5 103-114 
Frisch J, Venkatesan JK, Rey-Rico A, Schmitt G, Ma-
dry H & Cucchiarini M 2014b Determination of the 
chondrogenic differentiation processes in human bone 
marrow-derived mesenchymal stem cells genetically 
modified to overexpress transforming growth factor-b 
via recombinant adeno-associated viral vectors. Hum 
Gene Ther 25 1050-1060 
Funck-Brentano T, Bouaziz W, Marty C, Geoffroy V, 
Hay E & Cohen-Solal M 2014 Dkk-1-mediated inhibi-
tion of Wnt signaling in bone ameliorates osteoarthritis 
in mice. Arthritis Rheumatol 66 3028-3039 
Glinka A, Wu W, Delius H, Monaghan AP, Blumen-
stock C & Niehrs C 1998 Dickkopf-1 is a member of a 
new family of secreted proteins and functions in head 
induction. Nature 391 357-362 
Goldring MB, Fukuo K, Birkhead JR, Dudek E & San-
dell LJ 1994 Transcriptional suppression by inter-
leukin-1 and interferon-gamma of type II collagen 
gene expression in human chondrocytes. J Cell Bio-
chem 54 85-99 
Gregory CA, Singh H, Perry AS & Prockop DJ 2003 
The Wnt signaling inhibitor dickkopf-1 is required for 
reentry into the cell cycle of human adult stem cells 
from bone marrow. J Biol Chem 278 28067-28078 
Haleem-Smith H, Calderon R, Song Y, Tuan RS & 
Chen FH 2012 Cartilage oligomeric matrix protein 
enhances matrix assembly during chondrogenesis of 
human mesenchymal stem cells. J Cell Biochem 113 
1245-1252 
Hattori T, Müller C, Gebhard S, Bauer E, Pausch F, 
Schlund B, Bösl MR, Hess A, Surmann-Schmitt C, 
von der Mark H, de Crombrugghe B & von der Mark 
K 2010 SOX9 is a major negative regulator of carti-
lage vascularization, bone marrow formation and en-
dochondral ossification. Development 137 901-911 
Ikeda T, Kamekura S, Mabuchi A, Kou I, Seki S, Ta-
kato T, Nakamura K, Kawaguchi H, Ikegawa S & 
Chung UI 2004 The combination of SOX5, SOX6, and 
SOX9 (the SOX trio) provides signals sufficient for 
induction of permanent cartilage. Arthritis Rheum 50 
3561-3573 
Im GI & Quan Z 2010 The effects of Wnt inhibitors on 
the chondrogenesis of human mesenchymal stem cells. 
Tissue Eng Part A 16 2405-2413 
Im GI, Lee JM & Kim HJ 2011 Wnt inhibitors en-
hance chondrogenesis of human mesenchymal stem 
cells in a long-term pellet culture. Biotechnol Lett 33 
1061-1068 
Jeon SY, Park JS, Yang HN, Woo DG & Park KH 
2012 Co-delivery of SOX9 genes and anti-Cbfa-1 
siRNA coated onto PLGA nanoparticles for chondro-
genesis of human MSCs. Biomaterials 33 4413-4423 
Johnstone B, Alini M, Cucchiarini M, Dodge GR, Eg-
lin D, Guilak F, Madry H, Mata A, Mauck RL, Semino 
CE & Stoddart MJ 2013 Tissue engineering for articu-
lar cartilage repair--the state of the art. Eur Cell Mater 
25 248-267 
Kim HJ & Im GI 2011 Electroporation-mediated trans-
fer of SOX trio genes (SOX-5, SOX-6, and SOX-9) to 
enhance the chondrogenesis of mesenchymal stem 
cells. Stem Cells Dev 20 2103-2114 
Krause U, Ryan DM, Clough BH & Gregory CA 2014 
An unexpected role for a Wnt-inhibitor: Dickkopf-1 
triggers a novel cancer survival mechanism through 
modulation of aldehyde-dehydrogenase-1 activity. Cell 
Death Dis 5 e1093- e1104 
Leijten JC, Emons J, Sticht C, van Gool S, Decker E, 
Uitterlinden A, Rappold G, Hofman A, Rivadeneira F, 
Scherjon S, Wit JM, van Meurs J, van Blitterswijk CA 
& Karperien M 2012 Gremlin 1, frizzled-related pro-
tein, and Dkk-1 are key regulators of human articular 
cartilage homeostasis. Arthritis Rheum 64 3302-3312 
Leung VY, Gao B, Leung KK, Melhado IG, Wynn SL, 
Au TY, Dung NW, Lau JY, Mak AC, Chan D & 
Cheah KS 2011 SOX9 governs differentiation stage-
specific gene expression in growth plate chondrocytes 
via direct concomitant transactivation and repression. 
PLoS Genet 7 e1002356-e1002371 
69   Journal of Molecular Biochemistry, 2018 
Liu TM, Guo XM, Tan HS, Hui JH, Lim B & Lee EH 
2011 Zinc-finger protein 145, acting as an upstream 
regulator of SOX9, improves the differentiation poten-
tial of human mesenchymal stem cells for cartilage 
regeneration and repair. Arthritis Rheum 63 2711-2720 
Liu S, Zhang E, Yang M & Lu L 2014 Overexpression 
of Wnt11 promotes chondrogenic differentiation of 
bone marrow-derived mesenchymal stem cells in syn-
ergism with TGF-b. Mol Cell Biochem 390 123-131 
Liu P, Sun L, Chen H, Sun S, Zhou D, Pang B & 
Wang J 2015 Lentiviral-mediated multiple gene trans-
fer to chondrocytes promotes chondrocyte differentia-
tion and bone formation in rabbit bone marrow-derived 
mesenchymal stem cells. Oncol Rep 34 2618-2626 
Madry H, van Dijk CN & Mueller-Gerbl M 2010 The 
basic science of the subchondral bone. Knee Surg 
Sports Traumatol Arthrosc 18 419-433 
Madry H & Cucchiarini M 2016 Gene therapy for hu-
man osteoarthritis: principles and clinical translation. 
Expert Opin Biol Ther 16 331-346 
Mason JB, Gurda BL, Hankenson KD, Harper LR, 
Carlson CS, Wilson JM & Richardson DW 2017 
Wnt10b and Dkk-1 gene therapy differentially influ-
enced trabecular bone architecture, soft tissue integrity, 
and osteophytosis in a skeletally mature rat model of 
osteoarthritis. Connect Tissue Res 58 542-552 
Oh H, Chun CH & Chun JS 2012 Dkk-1 expression in 
chondrocytes inhibits experimental osteoarthritic carti-
lage destruction in mice. Arthritis Rheum 64 2568-
2578 
Pagnotto MR, Wang Z, Karpie JC, Ferretti M, Xiao X 
& Chu CR 2007 Adeno-associated viral gene transfer 
of transforming growth factor-beta1 to human mesen-
chymal stem cells improves cartilage repair. Gene Ther 
14 804-813 
Samulski RJ, Chang LS & Shenk T 1987 A recombi-
nant plasmid from which an infectious adeno-
associated virus genome can be excised in vitro and its 
use to study viral replication. J Virol 61 3096-3101 
Samulski RJ, Chang LS & Shenk T 1989 Helper-free 
stocks of recombinant adeno-associated viruses: nor-
mal integration does not require viral gene expression. 
J Virol 63 3822-3828 
Sandell LJ & Adler P 1999 Developmental patterns of 
cartilage. Front Biosci 4 D731-D742 
Skowroński J & Rutka M 2013 Osteochondral lesions 
of the knee reconstructed with mesenchymal stem cells 
- results. Ortop Traumatol Rehabil 15 195-204 
Steinert AF, Palmer GD, Pilapil C, Nöth U, Evans CH 
& Ghivizzani SC 2009 Enhanced in vitro chondro-
genesis of primary mesenchymal stem cells by com-
bined gene transfer. Tissue Eng Part A 15 1127-1139 
Steinert AF, Weissenberger M, Kunz M, Gilbert F, 
Ghivizzani SC, Göbel S, Jakob F, Nöth U & Rudert M 
2012. Indian hedgehog gene transfer is a chondrogenic 
inducer of human mesenchymal stem cells. Arthritis 
Res Ther 14 R168-R180 
Venkatesan JK, Ekici M, Madry H, Schmitt G, Kohn 
D & Cucchiarini M 2012 SOX9 gene transfer via safe, 
stable, replication-defective recombinant adeno-
associated virus vectors as a novel, powerful tool to 
enhance the chondrogenic potential of human mesen-
chymal stem cells. Stem Cell Res Ther 3 22-36 
Venkatesan JK, Frisch J, Rey-Rico A, Schmitt G, Ma-
dry H & Cucchiarini M 2017 Impact of mechanical 
stimulation on the chondrogenic processes in human 
bone marrow aspirates modified to overexpress sox9 
via rAAV vectors. J Exp Orthop 4 22-34 
Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, 
Nakamura Y & Horibe S 2004 Autologous bone mar-
row stromal cell transplantation for repair of full-
thickness articular cartilage defects in human patellae: 
two case reports. Cell Transplant 13 595-600 
Weng LH, Wang CJ, Ko JY, Sun YC & Wang FS 
2010 Control of Dkk-1 ameliorates chondrocyte apop-
tosis, cartilage destruction, and subchondral bone dete-
rioration in osteoarthritic knees. Arthritis Rheum 62 
1393-1402 
Xiao X, Li J & Samulski RJ 1996 Efficient long-term 
gene transfer into muscle tissue of immunocompetent 
mice by adeno-associated virus vector. J Virol 70 8098
-8108 
Yoo JU, Mandell I, Angele P & Johnstone B 2000 
Chondrogenitor cells and gene therapy. Clin Orthop 
Relat Res 379 S164-S170 
Zhong L, Huang X, Rodrigues ED, Leijten JC, Verrips 
T, El Khattabi M, Karperien M & Post JN 2016 En-
dogenous DKK1 and FRZB regulate chondrogenesis 
and hypertrophy in three-dimensional cultures of hu-
man chondrocytes and human mesenchymal stem 
cells. Stem Cells Dev 25 1808-1817 
Journal of Molecular Biochemistry, 2018   70 
